NATURIMMUN
Natural Killer Cell-Based Anti-Cancer Immunotherapies: Research training in molecular medicine and biotechnology business
| Coordinatore | MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 3˙526˙286 € |
| EC contributo | 3˙526˙286 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2012-ITN |
| Funding Scheme | MC-ITN |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-10-01 - 2016-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | coordinator | 450˙214.75 |
| 2 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 889˙734.10 |
| 3 |
INSTITUT PASTEUR
Organization address
address: RUE DU DOCTEUR ROUX 25-28 contact info |
FR (PARIS CEDEX 15) | participant | 515˙197.30 |
| 4 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 285˙056.62 |
| 5 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 285˙056.62 |
| 6 |
IPD-THERAPEUTICS BV
Organization address
address: ONDERWIJSBOULEVARD 219 contact info |
NL ('S HERTOGENBOSCH) | participant | 236˙861.45 |
| 7 |
UNIVERSIDAD POMPEU FABRA
Organization address
address: PLACA DE LA MERCE 10-12 contact info |
ES (BARCELONA) | participant | 226˙681.62 |
| 8 |
THE HEBREW UNIVERSITY OF JERUSALEM.
Organization address
address: GIVAT RAM CAMPUS contact info |
IL (JERUSALEM) | participant | 224˙613.84 |
| 9 |
MILTENYI BIOTEC GMBH
Organization address
address: FRIEDRICH EBERT STRASSE 68 contact info |
DE (BERGISCH GLADBACH) | participant | 222˙068.88 |
| 10 |
AFFIMED THERAPEUTICS AG
Organization address
address: IN NEUENHEIMER FELD 582 contact info |
DE (HEIDELBERG) | participant | 190˙800.72 |
| 11 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'In the research part we will deal with the basic principles of the innate immune defense used to control tumors and viral infections with a focus on NK and NK/T cells, including analysis of NK receptor genomics/epigenetics, gene polymorphisms/disease linkage, differentiation of hitherto unrecognized NK cell subpopulations and novel ligands for NK receptors exposed by tumor and/or virally infected cells. We will investigate the mechanisms installed by tumors and viruses to avoid or subvert immune defenses. This will include the investigation of the role of NK/T cell subpopulations in the defense against tumors and infections by herpes virus family members, some being involved in tumor formation, in the development of inflammatory diseases and/or constituting a frequent complication during tumor therapy. The project will support anti-tumor and anti-viral therapies by developing novel technology for NK cell generation from cord blood stem cells for NK cell infusions in patients, by genetic engineering of NK cells and by using NK receptors and their ligands to develop novel reagents for amplifying anti-tumor and -viral activities of NK/T cells. It will further undertake basic studies on the potential of the newly emerging iPS cell technology for reconstituting immune systems including NK cells in patients with hematologic cancers. All students of this ITN will be trained in state-of-the-art immunotechnology including wider aspects of molecular medicine at the individual partner universities. An exchange of students between the different partners will be organized to ensure that every participant will be trained in several laboratories/universities with different expertise. It will further include network-wide training modules with cutting-edge lectures of internationally recognized research experts in the field, state-of-the-art seminars in the front-line technologies used in this project as well as courses in genome-wide bioinformatics, business and patent rights.'